Hubrecht Organoid Technology and GlaxoSmithKline will together develop a human relevant Lung and Colon Immuno-Oncology model using Tumor Organoids, to better predict drug effectiveness for small molecule therapies.
Atherosclerosis is the main underlying cause of cardiovascular disease (CVD) and due to its multifactorial natural is often studied in animal models. Here the aim is to develop an innovative ex vivo system to study the atherosclerotic disease process based on the actual human atherosclerotic plaque. In line with the Transition to Animal-free Innovation (TPI), the aim is to develop a model that generates data on the effect of novel drugs that is highly translatable to the effect of the novel drug in the cardiovascular patient, while at the same time minimising the number of laboratory animals used. Moreover, the aim is to utilise this model to discover new biomarkers of successful treatment, which could expedite the transition of CVD therapeutic into clinical trial.
The IMAGEN consortium aims to improve diagnostics of patients with ciliopathies and tubulopathies, enhance quality of care, and translate genetic findings to personalised care by testing pharmacological treatment approaches based on patient-derived disease models.
Worldwide, venomous snakebites claim about 125.000 deaths and maim 450.000 people yearly, mostly in poor rural areas, for which there is no safe and adequate treatment. This situation will be alleviated by developing human antibodies which will be safe and much better than the current treatments.
The immune system has potent mechanisms with which it deals with intruding viruses, bacteria and tumors, protecting us from disease. However, tumors contain mutations leading to resistance to the immune system. The NextIO project aims to develop a medicine that restores the sensitivity of the cancer to the immune system.
Acute myeloid leukemia (AML) is a form of blood cancer that is still difficult to cure and better therapies against AML are clearly needed. As a continuation of a long-standing collaboration between the Schuringa lab at the UMCG and Janssen will exploit potential novel targets against leukemic stem cells.
Increasing evidence suggests that dynamic changes in the transcriptional state of specific cell-types plays a key role in determining disease outcomes. Here, cell-type specific changes will be detected in tuberous sclerosis complex cortical tubers and assessed if these cell-type changes are involved in the pathogenesis of epilepsy.
Catecholaminergic Polymorphic Tachycardia is a genetic cardiovascular disease, often leading to sudden cardiac death, which is particularly difficult to study. The combination of human beating cardiac cells from patients and innovative screening assays can help identifying arrhythmia and drugs to prevent it using a personalized approach.
The human pluripotent stem cell derived heart models will be used for a rapid evaluation of important COVID-19 therapies and develop SARS-COV-2 disease models to investigate how infection affects the heart. Impact beyond conventional approaches will be accelerated by providing data immediately relevant to clinicians, within months of the project start.
There is a high demand for SARS-CoV-2 antiviral therapies that may limit COVID-19 severity in susceptible individuals. In this project, epithelial models from nasal brushing obtained from SARS-CoV-2 infected individuals will be developed. These models may allow simulation of viral infections in a dish and selection of candidate antiviral drugs.